EGFR and adenocarcinoma: In NSCLC adenocarcinomas, more than 85% of common EGFR mutations confer sensitivity to EGFR‐tyrosine kinase inhibitors (TKIs), while the remaining ∼15% represent rare or uncommon EGFR mutations (Table 1) [10].